IPOs in the CRO market remain steady

InVentiv Health has filed paperwork for an initial public offering (IPO) worth up to $100 million, following in the footsteps of three other large private equity-backed CROs that have gone public in recent years. Analysts see strong financial activity on the horizon for the CRO industry. Healthcare investment experts anticipate other private equity firms, specifically those that have purchased CROs in the past six to eight years, will look for a return on those in­vestments in the near term, primarily through M&A activity or public stock options.

Overseas FDA data integrity warnings: Combating a surge

A surge in the number of FDA-issued data integrity violations to overseas drug manufacturers is prompting concerns about ramifications and conversa­tions about solutions. A recent PricewaterhouseCoopers (PwC) report stated the number of warning letters by regulators has risen from five in 2010-2012 to 24 in 2013-2015—and all but one were issued to facilities located outside of the U.S.

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.